PharmaJet Archives - BioTuesdays

Developments

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

PharmaJet launched a Phase 1 clinical study evaluating a Venezuelan Equine Encephalitis (VEE) DNA vaccine delivered via the company’s needle-free Precision Delivery Systems. The Phase 1 trial, sponsored by PharmaJet and...

November 17, 2023

Developments

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...

October 25, 2023

Developments

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

PharmaJet partner, Scancell, reported positive data from the first phase of a Phase 2 clinical trial evaluating PharmaJet’s needle-free vaccine delivery system for treatment of advanced melanoma. The Phase 2 study’s...

September 28, 2023

Executive Moves

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

PharmaJet appointed Nanette Cocero, Ph.D., a recognized leader in the global pharmaceutical industry with broad commercial and business experience coupled with an extensive clinical and scientific background, to the...

July 12, 2023

Developments

PharmaJet Tropis system authorized for 2 nucleic acid vaccines

PharmaJet’s Tropis system is now the exclusive intradermal delivery system for two authorized novel COVID-19 vaccines. They include: The world’s first plasmid DNA COVID-19 vaccine for administration in humans from Zydus...

June 28, 2023

Executive Moves

Marie Mazur appointed chair of PharmaJet board

PharmaJet named Marie Mazur, PharmD, chairwoman of the board, replacing Ron Lowy, who had chaired the board since 2011. “Marie’s experience and leadership will be of great benefit for our company as we are accelerating...

June 6, 2023

Executive Moves

PharmaJet names Nathalie Landry as CSO

PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...

May 2, 2023

Developments

PharmaJet to present immune response DNA vaccine data

Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...

April 4, 2023

Developments

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...

April 3, 2023

Developments

PharmaJet partner gets fast track for cancer vaccine

PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...

December 13, 2022

Tag - PharmaJet

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet partner, Scancell, posts positive data from Phase 2 advanced melanoma trial

Former Pfizer vaccine president Nanette Cocero joins PharmaJet board

PharmaJet Tropis system authorized for 2 nucleic acid vaccines

Marie Mazur appointed chair of PharmaJet board

PharmaJet names Nathalie Landry as CSO

PharmaJet to present immune response DNA vaccine data

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner gets fast track for cancer vaccine

General

More